Enzo Biochem, Inc. (NYSE:ENZ)
Enzo Biochem, Inc. reported recently improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.
Among the quarter’s highlights (all references are to sequential quarter over quarter results, normalized for an inventory charge and severance of $1.8 million where applicable):
- Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
- Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
- Company-wide, gross margin increased $2.0 million or 17%.
- Operating expenses decreased 7%, or to 57% of revenues, from 63%.
- EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
- Net loss for the quarter was reduced 70%.
Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
To learn more about ENZ visit: http://www.enzo.com
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.
Alzheimer's is not an everyday part of growing older, although the most significant known risk factor is increasing age, and most people with Alzheimer's are 65 and older. But Alzheimer's is not merely a sickness associated with aging. As much as a few percent of people with the actual illness possess early-onset Alzheimer's (also referred to as younger-onset), which regularly appears when someone is within their 40's or 50's.
Alzheimer's worsens after a while. Alzheimer's is a progressing ailment, in which symptoms slowly progress over a period of time. In its early stages, forgetfulness is slight, however with late-stage Alzheimer's a person is not able to carry on a conversation or react to their natural environment. Alzheimer's is considered the 6th leading source of death within the United States. Those that have Alzheimer's typically live 8 years after their signs or symptoms come to be obvious to others. Yet survival can vary from 3 to 20 years based on age and other health conditions.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
To learn more about PWRM visit: http://www.Power3Medical.com
Safe Bulkers, Inc. (NYSE:SB) announced that it has entered into a new period time charter for one of its 82,300 dwt Kamsarmax-class vessels, for a duration of 2 years with a forward delivery date in the third quarter of 2011, at a gross daily charter rate of $18,350, less 3.5% total commissions. The Company currently estimates that its contracted charter coverage, including newbuilds, as of December 14, 2010, is 82% for 2011, 61% for 2012 and 54% for 2013.
Safe Bulkers, Inc. provides marine drybulk transportation services worldwide. The company transports various bulk cargoes, such as coal, grain, and iron ore.
Chemspec International Limited (NYSE:CPC) a leading China-based contract manufacturer of highly-engineered specialty chemicals, announced that its Board of Directors has received a letter (the "Financing Letter"), from the Company's Chairman and Chief Executive Officer, Dr. Jianhua Yang. The Financing Letter provides certain information regarding the financing of a proposal from Dr. Yang to acquire certain outstanding shares of the Company in a "going private" transaction set forth in a proposal letter, dated November 11, 2010.
Chemspec International Limited, through its subsidiaries, engages in the design, manufacture, and sale of chemical compounds in the People's Republic of China.******
Japan Smaller Capitalization Fund Inc. (NYSE:JOF) announced that it would make an ordinary income distribution of $0.0796 per share to shareholders of record on December 23, 2010. The ex-dividend date is December 20, 2010. The distribution is payable on December 30, 2010. The Fund invests primarily in the securities of smaller capitalization companies in Japan and is designed for investors seeking long-term capital appreciation. The Manager of the Fund is Nomura Asset Management U.S.A. Inc., which is based in New York. Nomura Asset Management U.S.A. Inc. is a subsidiary of Nomura Asset Management Co., Ltd., which is one of the largest investment advisory companies in Japan in terms of assets under management and which serves as the Investment Adviser to the Fund.
Japan Smaller Capitalization Fund, Inc. is a close-ended equity mutual fund launched by Nomura Asset Management U.S.A. Inc. It is managed by Nomura Asset Management Co., Ltd.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).